Novozymes As B Stock Today
| NVZMF Stock | USD 58.50 0.30 0.51% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Novozymes is trading at 58.50 as of the 2nd of December 2024. This is a 0.51 percent decrease since the beginning of the trading day. The stock's lowest day price was 58.5. Novozymes has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Novozymes AS B are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 2nd of December 2024. Click here to learn more.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States.. The company has 222.86 M outstanding shares. More on Novozymes AS B
Moving together with Novozymes Pink Sheet
Moving against Novozymes Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novozymes Pink Sheet Highlights
| President | Tina Fanoe |
| Business Concentration | Specialty Chemicals, Basic Materials (View all Sectors) |
Novozymes AS B [NVZMF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Large-Cap' category with a current market capitalization of 13.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novozymes's market, we take the total number of its shares issued and multiply it by Novozymes's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novozymes AS B classifies itself under Basic Materials sector and is part of Specialty Chemicals industry. The entity has 222.86 M outstanding shares.
Novozymes AS B has accumulated about 1.01 B in cash with 4.01 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.67.
Check Novozymes Probability Of Bankruptcy
Ownership AllocationNovozymes AS B maintains a total of 222.86 Million outstanding shares. 30% of Novozymes outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novozymes Ownership Details
Novozymes AS B Risk Profiles
| Mean Deviation | 1.97 | |||
| Standard Deviation | 2.7 | |||
| Variance | 7.28 | |||
| Risk Adjusted Performance | (0.06) |
Novozymes Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novozymes without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
| All Next | Launch Module |
Novozymes Corporate Management
| Pedro Fernandes | Head America | Profile | |
| Tobias Bjorklund | Head of Investor Relations | Profile | |
| Ester Baiget | Pres CEO | Profile | |
| Tue Micheelsen | VP Marketing | Profile | |
| Sebastian Sderberg | VP Acquisitions | Profile | |
| Graziela Malucelli | Supply Operations | Profile |
Other Information on Investing in Novozymes Pink Sheet
Novozymes financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes security.